BRPI0816142A2 - Modulador de nrg1 para tratamento de distúrbios respiratórios. - Google Patents

Modulador de nrg1 para tratamento de distúrbios respiratórios.

Info

Publication number: BRPI0816142A2
Authority: BR; Brazil
Prior art keywords: nrg1; modulator; treatment; respiratory disorders; respiratory
Prior art date: 2007-08-24

Application number

BRPI0816142-9A2A

Other languages

English (en)

Inventor

Carol Elizabeth Jones

Alan Jackson

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-24

Filing date

2008-08-22

Publication date

2015-02-18

2008-08-22 Application filed by Novartis Ag filed Critical Novartis Ag

2015-02-18 Publication of BRPI0816142A2 publication Critical patent/BRPI0816142A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0816142-9A2A 2007-08-24 2008-08-22 Modulador de nrg1 para tratamento de distúrbios respiratórios. BRPI0816142A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07114972		2007-08-24
PCT/EP2008/061009 WO2009027332A1 (en)	2007-08-24	2008-08-22	A modulator of nrg1 for treatment of respiratory disorders

Publications (1)

Publication Number	Publication Date
BRPI0816142A2 true BRPI0816142A2 (pt)	2015-02-18

Family

ID=38668734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816142-9A2A BRPI0816142A2 (pt)	2007-08-24	2008-08-22	Modulador de nrg1 para tratamento de distúrbios respiratórios.

Country Status (11)

Country	Link
US (2)	US20110070247A1 (pt)
EP (1)	EP2192955A1 (pt)
JP (1)	JP2010536830A (pt)
KR (1)	KR20100046215A (pt)
CN (1)	CN101784302A (pt)
AU (1)	AU2008292262B2 (pt)
BR (1)	BRPI0816142A2 (pt)
CA (1)	CA2697378A1 (pt)
EA (1)	EA201000337A1 (pt)
MX (1)	MX2010002116A (pt)
WO (1)	WO2009027332A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103959065B (zh)	2011-10-06	2018-07-17	Aveo制药公司	预测肿瘤对抗erbb3抗体的应答
WO2015100459A2 (en)	2013-12-27	2015-07-02	Merrimack Pharmaceuticals, Inc.	Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en)	2015-06-04	2019-01-22	Merrimack Pharmaceuticals, Inc.	Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
DK3448391T3 (da)	2016-04-27	2024-06-24	Abbvie Mfg Management Unlimited Company	Fremgangsmåder til behandling af sygdomme med skadelig il-13-aktivitet under anvendelse af anti-il-13-antistoffer
WO2021142245A1 (en) *	2020-01-10	2021-07-15	Translate Bio, Inc.	Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US20050208527A1 (en) *	2000-02-28	2005-09-22	Decode Genetics Ehf.	Human schizophrenia gene
MXPA02008239A (es)	2000-02-28	2004-08-12	Decode Genetics Ehf	Gen humano de la esquizofrenia.
WO2006062135A1 (ja) *	2004-12-07	2006-06-15	Riken	精神疾患の診断薬
EP1856158A4 (en) *	2005-03-07	2010-07-28	Targeted Molecular Diagnostics	TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE
US20070036797A1 (en) *	2005-06-02	2007-02-15	Galaxy Biotech, Llc	Methods of treating brain tumors with antibodies
US20070213264A1 (en) *	2005-12-02	2007-09-13	Mingdong Zhou	Neuregulin variants and methods of screening and using thereof

2008
- 2008-08-22 EP EP08787411A patent/EP2192955A1/en not_active Withdrawn
- 2008-08-22 WO PCT/EP2008/061009 patent/WO2009027332A1/en active Application Filing
- 2008-08-22 CA CA2697378A patent/CA2697378A1/en not_active Abandoned
- 2008-08-22 CN CN200880104292A patent/CN101784302A/zh active Pending
- 2008-08-22 AU AU2008292262A patent/AU2008292262B2/en not_active Ceased
- 2008-08-22 MX MX2010002116A patent/MX2010002116A/es active IP Right Grant
- 2008-08-22 JP JP2010521437A patent/JP2010536830A/ja active Pending
- 2008-08-22 US US12/674,964 patent/US20110070247A1/en not_active Abandoned
- 2008-08-22 EA EA201000337A patent/EA201000337A1/ru unknown
- 2008-08-22 BR BRPI0816142-9A2A patent/BRPI0816142A2/pt not_active IP Right Cessation
- 2008-08-22 KR KR1020107003919A patent/KR20100046215A/ko not_active Application Discontinuation
2012
- 2012-08-07 US US13/568,300 patent/US8658165B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20130034567A1 (en)	2013-02-07
US8658165B2 (en)	2014-02-25
CN101784302A (zh)	2010-07-21
AU2008292262A1 (en)	2009-03-05
WO2009027332A1 (en)	2009-03-05
EA201000337A1 (ru)	2010-10-29
KR20100046215A (ko)	2010-05-06
EP2192955A1 (en)	2010-06-09
CA2697378A1 (en)	2009-03-05
MX2010002116A (es)	2010-03-26
US20110070247A1 (en)	2011-03-24
JP2010536830A (ja)	2010-12-02
AU2008292262B2 (en)	2012-05-31

Publication	Publication Date	Title
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
BRPI0918527A2 (pt)	2015-12-01	compostos para o tratamento de disturbios do cns
BRPI0919920A2 (pt)	2016-02-16	compostos para tratamento de doenças e desordens oftálmicas
BRPI0816784A2 (pt)	2015-03-24	Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0816712A2 (pt)	2016-11-08	terapia de intervalo para o tratamento de tinnitus
BRPI0919195A2 (pt)	2019-09-24	metodos e aparelhos para o tratamento de transtornos do ouvido, nariz e garganta
BRPI0816175A2 (pt)	2015-02-24	Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
BRPI0919288A2 (pt)	2015-12-15	teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0819630A2 (pt)	2015-05-05	Montagem de interface de paciente para terapia respiratória
EP2166837A4 (en)	2011-12-21	DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
BRPI0911577A2 (pt)	2016-01-05	derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0917567A2 (pt)	2015-11-17	tratamento de doença respiratória
BRPI0818109A2 (pt)	2016-03-22	corpo de máscara para meia-máscara respirátoria
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
BRPI0811581A2 (pt)	2014-12-09	Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
BRPI0906606A2 (pt)	2015-07-14	Tratamento terapêutico para condições do pulmão.
BRPI1013778A2 (pt)	2016-04-05	"equipamento para tratamento por imersão."
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BR112012003372A2 (pt)	2019-09-24	vitamina d3 e análogos da mesma para o tratamento de alopecia.
BRPI0818170A2 (pt)	2017-05-16	5-cianotienopiridinas para o tratamento de tumores.
BRPI1013245A2 (pt)	2016-04-05	"composto para o tratamento de distúrbios metabólicos"
BRPI0812040A2 (pt)	2014-10-21	Indicações para terapia de anti-il-i-beta
DK2117565T3 (da)	2012-11-19	Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.